Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Carcinoma, Hepatocellular × orantinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

Sorafenib 39 lenvatinib 19 Fluorouracil 14 Oxaliplatin 13 atezolizumab 12 Doxorubicin 12 Bevacizumab 11 Ethiodized Oil 10 Radiosurgery 9 Radiofrequency Ablation 9 Leucovorin 9 Folfox protocol 7 pembrolizumab 6 Epirubicin 6 Cisplatin 6 sintilimab 5 durvalumab 5 Radiotherapy 5 Gemcitabine 5 tremelimumab 4 apatinib 4 Nivolumab 4 Embolization, Therapeutic 4 camrelizumab 3 Tenofovir 3 Pharmaceutical Preparations 3 Mitomycin 3 Hepatectomy 3 Dexamethasone 3 Chemotherapy, Adjuvant 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01465464 2019-08-07

ORIENTAL

Taiho Pharmaceutical Co., Ltd.

Phase 3 Terminated

888 enrolled 12 charts

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡